View or download our Patient Dosing Guide Here
20 After 52 weeks, steatohepatitis resolved without fibrosis progression in 44%, 56%, and 62% of participants receiving tirzepatide at doses of 5 mg, 10 mg, and 15 mg, respectively, compared to 10% in the placebo group
## **Other similar codes** - **J0585** - Injection, onabotulinumtoxina, 1 unit - **J0586** - Injection, abobotulinumtoxina, 5 units - **J0587** - Injection, rimabotulinumtoxinb, 100 units - **J0638** - Injection, canakinumab, 1 mg - **J0584** - Injection, burosumab-twza 1 mg Frequently asked questions Related Procedure Codes EHR and practice management software Get started for free *No credit card required
Our GLP-1 ID approach to maintenance dosing provides: Individualized Care Model: Developed to reimagine metabolic and weight related care, the GLP-1 ID program combines medical precision with holistic support, delivering 46% better weight loss outcomes compared to traditional programs